UIC
TRIB

Uniplan Investment Counsel’s Trinity Biotech TRIB Stock Holding History

Uniplan Investment Counsel’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-52,373
Closed -$3M – 115
2015
Q3 		$3M Buy
52,373
+1,692
+3% +$136K 0.14% 101
2015
Q2 		$4.58M Buy
+50,681
New +$4.39M 0.21% 95

Other funds holding TRIB

Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Uniplan Investment Counsel's TRIB Position: Q4 2015 in Review

Uniplan Investment Counsel sold out of Trinity Biotech (TRIB) in Q4 2015, closing a stake of 52,373 shares — an estimated $3M sold.

Uniplan Investment Counsel first reported a position in TRIB in Q2 2015 and held it in 2 quarters. The position peaked at $4.58M in Q2 2015. 82 funds tracked by Wall St. Rank hold TRIB as of Q4 2015.

  • Uniplan Investment Counsel reported no remaining Trinity Biotech position as of Q4 2015 after selling out during the quarter.
  • Uniplan Investment Counsel sold 52,373 Trinity Biotech shares in Q4 2015, an estimated $3M.
  • Uniplan Investment Counsel first reported a position in Trinity Biotech in Q2 2015 and held it in 2 quarters.
  • Uniplan Investment Counsel's Trinity Biotech position peaked at $4.58M in Q2 2015.
  • 82 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2015.

Based on Uniplan Investment Counsel's 13F filing for Q4 2015, filed 11 Feb 2016.